Literature DB >> 8946834

Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice.

J Tian1, M Clare-Salzler, A Herschenfeld, B Middleton, D Newman, R Mueller, S Arita, C Evans, M A Atkinson, Y Mullen, N Sarvetnick, A J Tobin, P V Lehmann, D L Kaufman.   

Abstract

In nonobese diabetic (NOD) mice, beta-cell reactive T-helper type 1 (Th1) responses develop spontaneously and gradually spread, creating a cascade of responses that ultimately destroys the beta-cells. The diversity of the autoreactive T-cell repertoire creates a major obstacle to the development of therapeutics. We show that even in the presence of established Th1 responses, it is possible to induce autoantigen-specific anti-inflammatory Th2 responses. Immune deviation of T-cell responses to the beta-cell autoantigen glutamate decarboxylase (GAD65), induced an active form of self-tolerance that was associated with an inhibition of disease progression in prediabetic mice and prolonged survival of syngeneic islet grafts in diabetic NOD mice. Thus, modulation of autoantigen-specific Th1/Th2 balances may provide a minimally invasive means of downregulating established pathogenic autoimmune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946834     DOI: 10.1038/nm1296-1348

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  63 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire?

Authors:  M Peakman; C M Dayan
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

4.  Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice.

Authors:  S D Patel; A P Cope; M Congia; T T Chen; E Kim; L Fugger; D Wherrett; G Sonderstrup-McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 5.  GAD antigen and its significance in type I diabetes.

Authors:  M I Hawa; R D G Leslie
Journal:  J Endocrinol Invest       Date:  2002 Jul-Aug       Impact factor: 4.256

Review 6.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

Review 7.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

8.  AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice.

Authors:  Khaja K Rehman; Massimo Trucco; Zhong Wang; Xiao Xiao; Paul D Robbins
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

9.  L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart.

Authors:  Daniela Cihakova; Jobert G Barin; G Christian Baldeviano; Miho Kimura; Monica V Talor; Daniel H Zimmerman; Eyal Talor; Noel R Rose
Journal:  Int Immunopharmacol       Date:  2008-01-29       Impact factor: 4.932

10.  Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease.

Authors:  L Geng; M Solimena; R A Flavell; R S Sherwin; A C Hayday
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.